AIM ImmunoTech Inc.
AIM · XNYSCIK 946644fmd_0XDEKTZRRYQY7KFXWK8WAWVJ91Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | 0 | (0) | (2) | 0 | (0) | 0 |
| Research and development | 5 | 4 | 5 | 5 | 6 | 8 | 7 | 11 | 6 | 4 |
| Operating income | (14) | (11) | (11) | (12) | (15) | (19) | (20) | (32) | (20) | (12) |
| Interest expense | – | 0 | 0 | 0 | 1 | 0 | – | – | 1 | 1 |
| Interest and investment income | 0 | 0 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | – | – | – | – | – | 1 | 1 | 5 | 3 |
| Income before taxes | – | – | – | – | – | – | – | – | – | (14) |
| Net income | (8) | (8) | (10) | (9) | (14) | (19) | (19) | (29) | (17) | (14) |